Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MSD, Mylan Terminate Promotional Contract for Lipovas and Renivase
October 24, 2011
- Astellas Recalls Tacrolimus in Japan, Europe After Dissolution Test Standards Unmet
October 24, 2011
- SymBio’s Bendamustine Gets NDA Approval in Taiwan
October 24, 2011
- US Baxter International Initiates PIII Clinical Trial for Blood Disorder Treatment Drug
October 24, 2011
- Otsuka Confirms Efficacy of Rotigotine for RLS in Domestic PIII Clinical Study
October 21, 2011
- Ono Upwardly Revises Sales Forecast Due to Main Product Growth
October 21, 2011
- Abbott to Separate into 2 Companies
October 21, 2011
- Chugai Tops Patent Asset Rankings, Teijin Jumps to Second Place
October 21, 2011
- No. of Latuda Prescriptions to Potentially Exceed Forecast: Nomura Securities
October 21, 2011
- Takeda Positions “Enbrel MRs” in Boosted Cooperation Efforts with Pfizer
October 20, 2011
- Otsuka to Set Up Joint Venture Company to Develop, Commercialize Pancreatic Islet Cells
October 20, 2011
- Growell to Introduce T-Point Service for Copayments of Ethical Drugs
October 20, 2011
- Sanofi Signs Comprehensive Contract with Kyoto Univ. on Life Science Research
October 19, 2011
- Takeda Initiates PIII Clinical Trials for Antidiabetic TAK-875 in US, Europe
October 19, 2011
- JT to Cease Development of Osteoporosis Treatment following Termination of License Agreement with Merck
October 19, 2011
- UCB Japan Reorganizes Sales & Marketing Division to Enhance Specialization
October 19, 2011
- SSP Aims for 10% Market Share with Switch OTC Alesion 10
October 19, 2011
- Japan, a Strategic Country Where Growth is Expectable: New AZ President Hudson
October 18, 2011
- MTPC Aims at Sales of ¥500 Bil. in FY2015
October 18, 2011
- MTPC Aims to Initiate Clinical Studies for 3 Compounds per Year
October 18, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…